Literature DB >> 11120856

Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease.

T Parrello1, G Monteleone, S Cucchiara, I Monteleone, L Sebkova, P Doldo, F Luzza, F Pallone.   

Abstract

Crohn' s disease (CD) is a chronic intestinal inflammatory disorder characterized by aberrant mucosal Th1 cell activation and production of IL-12, the major Th1-driving factor. The T cell response to IL-12 is dependent on the expression of a specific receptor composed of two subunits, termed IL-12Rbeta1 and IL-12Rbeta2. The content of IL-12Rbeta2, as measured at the mRNA level, is crucial in regulating Th1 differentiation. In this study we therefore investigated IL-12Rbeta2 RNA transcripts in CD. IL-12Rbeta2 expression was increased in active CD as well as Helicobacter pylori (HP)-associated gastritis and Salmonella colitis compared with that in inactive CD, ulcerative colitis, noninflammatory controls, and celiac disease. In contrast, IL-12Rbeta1 transcripts were expressed at comparable levels in all samples. In CD, IL-12Rbeta2 expression strictly correlated with tyrosine phosphorylation of STAT4, a key component of the IL-12-dependent Th1 polarization. This was associated with a pronounced expression of IFN-gamma. Transcripts for IL-12/p40 were detected in CD, HP-positive, and Salmonella colitis patients, but not in celiac disease, indicating that IL-12Rbeta2 up-regulation occurs only in IL-12-associated Th1 gastrointestinal diseases. Finally, we showed that stimulation of lamina propria mononuclear cells with IL-12 enhanced IL-12Rbeta2, suggesting that IL-12 regulates IL-12Rbeta2 expression in human gastrointestinal mucosa. The data show that the signaling pathway used by IL-12 to induce Th1 differentiation is increased at the site of disease in CD, further supporting the view that IL-12/IL-12R signals contribute to the inflammatory response in this condition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120856     DOI: 10.4049/jimmunol.165.12.7234

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.

Authors:  J Bauditz; S Wedel; H Lochs
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon.

Authors:  D Berrebi; R Maudinas; J-P Hugot; M Chamaillard; F Chareyre; P De Lagausie; C Yang; P Desreumaux; M Giovannini; J-P Cézard; H Zouali; D Emilie; M Peuchmaur
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

3.  T helper cell polarisation in coeliac disease: any (T-)bet ?

Authors:  M H Holtmann; M F Neurath
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 4.  Immunopathogenesis of IBD: insufficient suppressor function in the gut?

Authors:  I L Huibregtse; A U van Lent; S J H van Deventer
Journal:  Gut       Date:  2006-10-17       Impact factor: 23.059

Review 5.  Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication.

Authors:  Ilaria Peluso; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

6.  Systematic functional regulatory assessment of disease-associated variants.

Authors:  Konrad J Karczewski; Joel T Dudley; Kimberly R Kukurba; Rong Chen; Atul J Butte; Stephen B Montgomery; Michael Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-20       Impact factor: 11.205

7.  Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals.

Authors:  S Jarefors; C K Janefjord; P Forsberg; M C Jenmalm; C Ekerfelt
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

8.  STAT4 isoforms differentially regulate Th1 cytokine production and the severity of inflammatory bowel disease.

Authors:  John T O'Malley; Rajaraman D Eri; Gretta L Stritesky; Anubhav N Mathur; Hua-Chen Chang; Harm Hogenesch; Mythily Srinivasan; Mark H Kaplan
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

Review 9.  Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases.

Authors:  Flavio Caprioli; Roberta Caruso; Massimiliano Sarra; Francesco Pallone; Giovanni Monteleone
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

10.  Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease.

Authors:  E M Coccia; M E Remoli; C Di Giacinto; B Del Zotto; E Giacomini; G Monteleone; M Boirivant
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.